IL-8, IL-10, TGF-<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M1"><mml:mrow><mml:mi mathvariant="bold-italic">β</mml:mi></mml:mrow></mml:math>, and GCSF Levels Were Increased in Severe Persistent Allergic Asthma Patients with the Anti-IgE Treatment

  • Arzu D. Yalcin
    Allergy and Clinical Immunology Unit, Department of Internal Medicine, Antalya Training and Research Hospital, 07070 Antalya, Turkey
  • Atil Bisgin
    Department of Clinical and Experimental Medicine, Faculty of Health Sciences, Linköping University, 58185 Linköping, Sweden
  • Reginald M. Gorczynski
    Division of Cellular and Molecular Biology, Toronto Hospital, University Health Network, Toronto, ON, Canada M5G 2C4

書誌事項

公開日
2012
権利情報
  • http://creativecommons.org/licenses/by/3.0/
DOI
  • 10.1155/2012/720976
公開者
Wiley

この論文をさがす

説明

<jats:p><jats:italic>Background</jats:italic>. Allergic asthma is showed an increase in Th2-cytokine and IgE levels and an accumulation activation of Th2 cells, eosinophils and mast cells. However, recent studies focused on cell-based mechanisms for the pathogenesis of allergic asthma.<jats:italic>Objectives</jats:italic>. In this study, we compare the anti-IgE treatment modality in the dynamics of immune system cytokine levels in severe persistent asthma (SPA) patients who had no other any allergic disease, newly diagnosed allergic asthma patients and healthy volunteers.<jats:italic>Study Design</jats:italic>. The study population consisted of 14 SPA patients, 14 newly diagnosed allergic asthma patients and 14 healthy volunteers included as controls. Cytokine levels were measured. Total and specific IgE levels of anti-IgE monoclonal antibody treated patients, serum high-sensitivity C-reactive protein (hsCRP) levels, FEV1/FVC rates and asthma control test (ACT) were measured for the clinical follow-up.<jats:italic>Results</jats:italic>. We observed that SPA patients presented increasing levels of IL-8, IL-10, TGF-<jats:italic>β</jats:italic>and GCSF during the anti-IgE treatment in period of sampling times at 4 months and 18 months. However this increase was not correlated neither with serum hsCRP levels nor FEV1/FVC rates.<jats:italic>Conclusions</jats:italic>. Our study gives a different perspective for the SPA and anti-IgE immunotherapy efficacy at the cell cytokine-linked step.</jats:p>

収録刊行物

被引用文献 (1)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ